IASO BioMed (IASO) 10-Q 17 May 19 2019 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2019	May 15, 2019
Document And Entity Information
Entity Registrant Name	IASO BioMed, Inc.
Entity Central Index Key	0001662907
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		37,248,744
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2019

Condensed Balance Sheets (Unaud

Condensed Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
CURRENT ASSETS:
Cash	$ 78,174	$ 140,234
Prepaid expenses		1,451
Total current assets	78,174	141,685
TOTAL ASSETS	78,174	141,685
CURRENT LIABILITIES:
Accounts payable	133,400	92,901
Accounts payable, related party	55,000	43,000
Note payable, related party	60,000	60,000
Accrued salaries	458,750	402,500
Accrued board fees	155,000	140,000
Accrued interest, related party	6,691	5,803
Total current liabilities	868,841	744,204
TOTAL LIABILITIES	868,841	744,204
COMMITMENTS AND CONTINGENCIES (Note 5)
STOCKHOLDERS' DEFICIT:
Preferred stock, $.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding
Common stock, $.0001 par value, 100,000,00 shares authorized; 37,248,744 and 35,952,632 shares issued and outstanding	3,725	3,595
Additional paid-in capital	2,437,432	2,435,051
Accumulated deficit	(3,231,824)	(3,041,165)
Total shareholders' deficit	(790,667)	(602,519)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 78,174	$ 141,685

Condensed Balance Sheets (Una_2

Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ .0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, Shares outstanding
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	37,248,744	35,952,632
Common stock, shares outstanding	37,248,744	35,952,632

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
Revenues
Operating expenses:
General and administrative	137,771	540,357
Professional and consulting expense, related party	17,000	5,000
Research and development	35,000	10,000
Total operating expenses	189,771	555,357
Loss From Operations	(189,771)	(555,357)
Other Expenses:
Interest expense, related party	888	888
Total other expenses	888	888
Net Loss	$ (190,659)	$ (556,245)
Earnings per Common Share:
Basic and diluted loss per share	$ (0.01)	$ (0.02)
Weighted average number of common Shares outstanding:
Basic and diluted	37,048,417	34,527,632

Condensed Statement of Stockhol

Condensed Statement of Stockholders' Deficit (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2017	$ 3,425	$ 1,108,126	$ (1,403,928)	$ (292,377)
Balance, shares at Dec. 31, 2017	33,252,632
Sale of common stock	$ 25	99,975		100,000
Sale of common stock, shares	25,000
Warrant exercises	$ 40	3,960		4,000
Warrant exercises, shares	400,000
Share-based compensation		357,428		357,428
Net loss			(556,245)	(556,245)
Balance at Mar. 31, 2018	$ 3,490	1,569,489	(1,960,173)	(387,194)
Balance, shares at Mar. 31, 2018	33,902,632
Balance at Dec. 31, 2018	$ 3,595	2,435,051	(3,041,165)	(602,519)
Balance, shares at Dec. 31, 2018	35,952,632
Warrant exercises	$ 130	2,381		2,511
Warrant exercises, shares	1,296,112
Share-based compensation
Net loss			(190,659)	(190,659)
Balance at Mar. 31, 2019	$ 3,725	$ 2,437,432	$ (3,231,824)	$ (790,667)
Balance, shares at Mar. 31, 2019	37,248,744

Condensed Statement of Cash Flo

Condensed Statement of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash Flows from Operating Activities:
Net loss	$ (190,659)	$ (556,245)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation		357,428
Changes in assets and liabilities:
Prepaid expenses	1,451	1,407
Accounts payable	52,499	(30,930)
Accrued salaries	56,250	56,250
Accrued board fees	15,000	105,000
Accrued interest, related party	888	888
Net cash used in operating activities	(64,571)	(66,202)
Cash Flows from Financing Activities:
Proceeds from sale of common stock		100,000
Proceeds from the exercise of warrants	2,511	4,000
Net cash provided by financing activities	2,511	104,000
Net Increase (Decrease) in Cash	(62,060)	37,798
Cash, beginning of period	140,234	20,191
Cash, end of period	$ 78,174	$ 57,989

Nature of Operations and Summar

Nature of Operations and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Nature of Operations and Summary of Significant Accounting Policies	1. Nature of Operations and Summary of Significant Accounting Policies Nature of Operations rd Basis of presentation In the opinion of management, all adjustments (consisting only of normal recurring adjustments) which are necessary to provide a fair presentation of operating results for the interim periods presented have been made. The results of operations for the periods presented are not necessarily indicative of the results to be expected for the year. Reclassification Cash and Cash Equivalents Use of Estimates Research and Development Costs Share-based Compensation The Company uses the Black-Scholes option-pricing model to estimate the fair value of warrants and the market price of our common stock, or comparable public companies if our stock is not trading, on the date of grant for the fair value. Our determination of fair value of share-based awards is affected by those stock prices as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, our expected stock price volatility over the term of the awards, and certain other market variables such as the risk-free interest rate. Income Taxes Fair Value of Financial Instruments Earning (Loss) Per Share Recently Issued Accounting Pronouncements Leases In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. It is effective prospectively for the annual period ending September 30, 2019 and interim periods within that annual period. Early adoption is permitted. The Company does not expect ASU 2017-09 will have a significant impact on its financial statements upon adoption.

Going Concern

Going Concern	3 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	2. Going Concern At March 31, 2019 and December 31, 2018, the Company had cash of $78,174 and $140,234, respectively. It also had a working capital deficit of $790,667 and $602,519, respectively and an accumulated deficit of $3,231,824 and $3,041,165, respectively. This raises substantial doubt about the Company’s ability to continue as a going concern. Management is taking action to ensure the Company will continue as a going concern for at least one year beyond the date of the issuance of the Company’s financial statements. From March 11, 2015 (Inception) through March 31, 2019, the Company sold $971,842 in common stock. Common stock sales continue pursuant to private placement and other potential equity offerings. These fundraising efforts may not be successful. While there can be no assurances, management believes that these actions will enable the Company to continue as a going concern. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	3. Related Party Transactions Note Payable In October 2017, the Company executed an unsecured promissory note to Richard Schell for $35,000 bearing interest at 6% per annum, which remained outstanding at March 31, 2019 and December 31, 2018 with accrued interest payable of $3,124 and $2,606, respectively. A total of $888 of interest expense was accrued during each of the three-month periods ended March 31, 2019 and 2018, respectively. Employment Agreements In March 2017 the Company entered into an employment agreement with its CFO for a two-year term, which term was extended by our board of directors in January 2019 for an additional two-year term until March 2021. The CFO will assume his responsibilities on a part time basis until requested by the Board of Directors to become a full-time executive. The base salary of $75,000 per annum is payable to the CFO only upon the Company’s raising of an additional $750,000. When the CFO becomes a full-time executive, his salary will be increased to $125,000 per annum. The CFO also received warrants to purchase 500,000 shares of the Company’s common stock at $0.40 per share for a period of five years after issuance. 250,000 warrants vested upon signing the agreement and the remaining 250,000 vested in March 2018. The CFO will also be eligible to earn discretionary annual performance bonuses upon meeting certain objectives as determined by the Board of Directors, none of which have been granted to date. The agreement provides for severance payments. The Company accrued $56,250 in salaries related to these agreements in each of the three-month periods ended March 31, 2019 and 2018, respectively. Scientific Advisory Board Agreements Also, effective March 1, 2018, we entered into a Scientific Advisory Board Agreement with our director Dr. Karatzas (the “Karatzas Agreement”), through which Dr. Karatzas agreed to serve on our Scientific Advisory Board. The term of the Karatzas Agreement is one year from execution and may be renewed annually by mutual consent of both parties. The Karatzas Agreement provides for payments as follows: an annual fee of $25,000; a signing bonus of $50,000 payable after successful closing of any cumulative minimum $1,000,000 investment in the Company; a non-discretionary bonus of $40,000 payable following a successful financing round of a minimum of $2,000,000; and should the Karatzas Agreement be renewed after one year, a $90,000 bonus payable only after the signing bonus and non-discretionary bonus from year one have been earned. In order to receive the non-discretionary bonus payments Dr. Karatzas must be actively involved in the creation and execution of strategies necessary for the Company to achieve its strategic plan including the scientific, commercial and business objectives, as applicable and as agreed upon between the Dr. Karatzas and the Company’s Chief Executive Officer. In January 2019, this agreement was extended for an additional year under the same terms and conditions and will expire in February 2020. The Company accrued a total of $15,000 in fees related to these agreements for the three-month period ended March 31, 2019, and accrued $105,000 in fees related to these agreements in the three-month period ended March 31, 2018, which included $5,000 in fees and $100,000 in signing bonuses. Services Agreement he Company pays the Company’s Corporate Secretary’s company $400 per month for reimbursement of certain administrative charges such as computer, internet, phone and similar items. The agreement is on a month-to-month basis and may be terminated at any time by either party. Total expense for the three months ended March 31, 2019 and 2018 was $1,200. Consulting Agreement and other Payments Warrants In October 2018, our board of directors issued our corporate secretary a warrant to purchase up to 211,112 shares of our common stock for a period of three months at an exercise price of $0.001 per share. These warrants were exercised in January 2019. These warrants were determined by the Company to have a fair market value of $84,236 using the Black-Scholes option pricing model.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2019
Equity [Abstract]
Stockholders' Equity	4. Stockholders’ Equity The Company has the authority to issue 110,000,000 shares of $.0001 par value stock, of which 100,000,000 shares are common stock and 10,000,000 shares are preferred stock. As of March 31, 2019, and December 31, 2018 there were 37,248,744 and 35,952,632 common stock shares issued and outstanding. For the three-month period ended March 31, 2018, the Company sold $100,000 in its private placement, issuing 250,000 shares of our common stock at $0.40 per share that included warrants to purchase up to 250,000 shares of our common stock exercisable at $0.75 per share for a period of three years from issuance. During the three-month period ended March 31, 2018, the Company issued warrants to purchase up to 860,000 shares of common stock at an exercise price of $0.01 per share to business, legal and scientific consultants; 400,000 of which were to expire in December 2022 and 460,000 of which expire in February 2021. Subsequent to issuance, 400,000 of these warrants were exercised for proceeds to the Company of $4,000. We incurred stock compensation expense totaling $336,926 in connection with the issuance of these warrants as more fully explained in Note 6 – Share-based Compensation. On November 1, 2018, the Registrant’s Board approved the issuance of warrants to purchase shares of the Company’s common stock to two of its executive officers. Mr. Duane C. Knight, Chief Financial Officer of the Registrant, received a warrant to purchase up to 950,000 shares of common stock exercisable for period of three months at an exercise price of $0.001 per share. Mr. Thomas B. Olson, Corporate Secretary of the Registrant, received a warrant to purchase up to 211,112 shares of common stock exercisable for period of three months at an exercise price of $0.001 per share. Messrs. Knight and Olson exercised these warrants in January 2019 for total proceeds to the company of $1,161. In January 2019 we issued 135,000 shares upon the exercise of warrants to purchase 135,000 shares issued in September and October 2018 at an exercise price of $0.01 per share for total proceeds to the Company of $1,350.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	5. Commitments and Contingencies Royalties ● CAD $5,000 on the issuance of the first US patent that accrued US$3,750 in the first quarter of 2019 ● CAD $25,000 on the filing of an investigational new drug application or regulatory filing ● CAD $50,000 on the initiation of the first Phase II clinical study ● CAD $100,000 on the initiation of the first Phase III clinical study ● CAD $300,000 on receipt of regulatory approval The Company must also pay milestone payments as follows for the out of body test to identify Alzheimer’s disease as follows: ● CAD $5,000 on the issuance of the first US patent ● CAD $50,000 on the filing of a 510(k) or PMA application ● CAD $200,000 on receipt of regulatory approval In addition, the Company issued 5% of the total number of issued and outstanding shares in the Company’s Series A financing to the same institution, or 1,652,632 shares in March 2016. This agreement, payable in Canadian dollars, exposes the Company to foreign exchange transaction gains and losses. In August 2016, the Company issued an additional 300,000 shares of the Company’s common stock to McGill in lieu of the pre-existing anti-dilution provision. As McGill owns more than 5% of the Company’s outstanding common stock, it is considered a related party. Research Agreement Scientific Advisory Board

Share-based Compensation

Share-based Compensation	3 Months Ended
	Mar. 31, 2019
Share-based Payment Arrangement [Abstract]
Share-based Compensation	6. Share-based Compensation In March 2017, the Company issued 750,000 warrants to the Company’s officers to purchase shares of our common stock at $0.40 per share. Estimated fair values of warrants granted were determined using the Black-Scholes option pricing model with the following average assumptions: Risk-free interest rate 1.55 % Expected term 3 years Volatility 154 % Dividend yield - Fair value $ 0.33 Expected term represents the period that the Company’s stock-based awards are expected to be outstanding. The Company’s historical stock warrant exercise experience does not provide a reasonable basis upon which to estimate expected term. As such, the simplified method was used to calculate the expected term. The Company calculated volatility based on the volatilities of comparable public companies. Total share-based compensation related to these warrants was $20,502 for the three-months ended March 31, 2018. In February and March 2018 the Company issued warrants to purchase up to 860,000 shares of common stock at an exercise price of $0.01 per share to business, legal and scientific consultants; 400,000 of which were to expire in December 2022 and 460,000 of which expire in February 2021. Estimated fair values of warrants granted were determined using the Black-Scholes option pricing model with the following average assumptions: Risk-free interest rate 2.33 – 2.34 % Expected term 2.5 years Volatility 182 – 217 % Dividend yield - Fair value $ 0.39 Expected term represents the period that the Company’s stock-based awards are expected to be outstanding. The Company’s historical stock warrant exercise experience does not provide a reasonable basis upon which to estimate expected term. As such, the simplified method was used to calculate the expected term. The Company calculated volatility based on the volatilities of comparable public companies. Total share-based compensation related to these warrants was $336,926 for the three months ended March 31, 2018. We incurred no share-based compensation in the three-month period ended March 31, 2019.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	7. Subsequent Events Management has determined that there are no further events subsequent to the balance sheet date that should be disclosed in these financial statements.

Nature of Operations and Summ_2

Nature of Operations and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Nature of Operations	Nature of Operations rd
Basis of Presentation	Basis of presentation In the opinion of management, all adjustments (consisting only of normal recurring adjustments) which are necessary to provide a fair presentation of operating results for the interim periods presented have been made. The results of operations for the periods presented are not necessarily indicative of the results to be expected for the year.
Reclassification	Reclassification
Cash and Cash Equivalents	Cash and Cash Equivalents
Use of Estimates	Use of Estimates
Research and Development Costs	Research and Development Costs
Share-based Compensation	Share-based Compensation The Company uses the Black-Scholes option-pricing model to estimate the fair value of warrants and the market price of our common stock, or comparable public companies if our stock is not trading, on the date of grant for the fair value. Our determination of fair value of share-based awards is affected by those stock prices as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, our expected stock price volatility over the term of the awards, and certain other market variables such as the risk-free interest rate.
Income Taxes	Income Taxes
Fair Value of Financial Instruments	Fair Value of Financial Instruments
Earning (Loss) Per Share	Earning (Loss) Per Share
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements Leases In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. It is effective prospectively for the annual period ending September 30, 2019 and interim periods within that annual period. Early adoption is permitted. The Company does not expect ASU 2017-09 will have a significant impact on its financial statements upon adoption.

Share-based Compensation (Table

Share-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2019
Share-based Payment Arrangement [Abstract]
Schedule of Estimated Fair values of Warrants Granted Using the Black-Scholes Option Pricing Model	Estimated fair values of warrants granted were determined using the Black-Scholes option pricing model with the following average assumptions: Risk-free interest rate 1.55 % Expected term 3 years Volatility 154 % Dividend yield - Fair value $ 0.33 Estimated fair values of warrants granted were determined using the Black-Scholes option pricing model with the following average assumptions: Risk-free interest rate 2.33 – 2.34 % Expected term 2.5 years Volatility 182 – 217 % Dividend yield - Fair value $ 0.39

Nature of Operations and Summ_3

Nature of Operations and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Accounting Policies [Abstract]
Research and development costs	$ 35,000	$ 10,000
Antidilutive securities excluded from computation of earnings per share, amount	11,100,000	9,620,000

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	49 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 78,174	$ 140,234
Working capital deficit	790,667	602,519
Accumulated deficit	(3,231,824)	$ (3,041,165)
Sold common stock, value	$ 971,842

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Mar. 01, 2018	Oct. 31, 2018	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2019	Mar. 31, 2018	Jan. 02, 2019	Dec. 31, 2018	Oct. 31, 2017	Oct. 31, 2016
Related Party Transaction [Line Items]
Interest expense					$ 888	$ 888
Warrants to purchase common stock			250,000			250,000
Warrants [Member]
Related Party Transaction [Line Items]
Warrants to purchase common stock							135,000
Papadopoulos Agreement [Member]
Related Party Transaction [Line Items]
Annual fees	$ 35,000					$ 5,000
Amount awarded to serve as scientific advisory board	10,000
Signing bonus payable on closing of cumulative minimum investment	50,000					100,000
Cumulative minimum investment	1,000,000
Non-discretionary bonus	45,000
Financing round of minimum payment	2,000,000
Bonus payable	95,000
Accrued fees					15,000	105,000
Karatzas Agreement [Member]
Related Party Transaction [Line Items]
Annual fees	25,000
Signing bonus payable on closing of cumulative minimum investment	50,000
Cumulative minimum investment	1,000,000
Non-discretionary bonus	40,000
Financing round of minimum payment	2,000,000
Bonus payable	$ 90,000
Services Agreement [Member]
Related Party Transaction [Line Items]
Reimbursement charges per month					400
Reimbursement Expense					1,200	1,200
Consulting Agreement and Other Payments [Member]
Related Party Transaction [Line Items]
Accrued fees					5,000
Agreement related fees					5,000
Additional consulting services fee paid					2,000
Consulting Agreement and Other Payments [Member] | March 1, 2018 [Member]
Related Party Transaction [Line Items]
Accrued fees					15,000
Agreement related fees					5,000
Richard Schell, CEO [Member]
Related Party Transaction [Line Items]
Note payable, related party										$ 25,000
Notes payable, bearing interest percentage										6.00%
Accrued interest payable					3,567			$ 3,197
Richard Schell, CEO [Member] | Employment Agreement [Member]
Related Party Transaction [Line Items]
Agreement term				2 years
Base salary				$ 150,000
Additional capital to be raised as target				$ 750,000
Warrants to purchase common stock				250,000
Warrants, exercise price				$ 0.40
Warrants term				5 years
Richard Schell, CEO [Member] | Employment Agreement [Member] | Warrants [Member]
Related Party Transaction [Line Items]
Warrants, vested			125,000	125,000
Richard Schell, CEO [Member] | Unsecured Promissory Note [Member]
Related Party Transaction [Line Items]
Note payable, related party									$ 35,000
Notes payable, bearing interest percentage									6.00%
Accrued interest payable					3,124			$ 2,606
CFO [Member]
Related Party Transaction [Line Items]
Warrants to purchase common stock		950,000
Warrants, exercise price		$ .001
Warrants fair market value		$ 379,062
CFO [Member] | Employment Agreement [Member]
Related Party Transaction [Line Items]
Agreement term				2 years
Base salary				$ 75,000
Additional capital to be raised as target				$ 750,000
Warrants to purchase common stock				500,000
Warrants, exercise price				$ 0.40
Increase salary per annum				$ 125,000
CFO [Member] | Employment Agreement [Member] | Warrants [Member]
Related Party Transaction [Line Items]
Warrants, vested			250,000	250,000
CEO and CFO [Member] | Employment Agreement [Member]
Related Party Transaction [Line Items]
Compensation expenses					$ 56,250	$ 56,250
Board of Directors [Member]
Related Party Transaction [Line Items]
Warrants to purchase common stock		211,112
Warrants fair market value		$ 84,236

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Jan. 31, 2019	Mar. 31, 2019	Mar. 31, 2018	Jan. 02, 2019	Dec. 31, 2018	Nov. 02, 2018	Feb. 28, 2018
Class of Stock [Line Items]
Number of shares authorized to issue		110,000,000			110,000,000
Common stock, par value		$ 0.0001			$ 0.0001
Common stock, shares authorized		100,000,000			100,000,000
Preferred stock, shares authorized		10,000,000			10,000,000
Common stock, shares issued		37,248,744			35,952,632
Common stock, shares outstanding		37,248,744			35,952,632
Stock price per share			$ 0.40
Warrants issued to purchase common stock			250,000
Warrants exercise price			$ 0.75
Proceeds from the exercise of warrants		$ 2,511	$ 4,000
Stock compensation expense			$ 336,926
Warrants [Member]
Class of Stock [Line Items]
Warrants issued to purchase common stock				135,000
Warrants exercise price				$ 0.01
Proceeds from the exercise of warrants	$ 1,350
Warrants exercised	135,000
Business, Legal and Scientific Consultants [Member]
Class of Stock [Line Items]
Warrants issued to purchase common stock			860,000				860,000
Warrants exercise price			$ 0.01				$ 0.01
Stock compensation expense		$ 336,926
Business, Legal and Scientific Consultants [Member] | Warrants [Member]
Class of Stock [Line Items]
Warrants issued to purchase common stock			860,000
Warrants exercise price			$ 0.01
Business, Legal and Scientific Consultants [Member] | December 2022 [Member] | Warrants [Member]
Class of Stock [Line Items]
Warrants issued to purchase common stock			400,000
Warrants expiration date		Dec. 31, 2022
Business, Legal and Scientific Consultants [Member] | February 2021 [Member] | Warrants [Member]
Class of Stock [Line Items]
Warrants issued to purchase common stock			460,000
Warrants expiration date		Feb. 28, 2021
Mr. Duane C. Knight [Member]
Class of Stock [Line Items]
Warrants issued to purchase common stock						950,000
Warrants exercise price						$ 0.001
Warrants term period						3 months
Mr. Thomas B. Olson [Member]
Class of Stock [Line Items]
Warrants issued to purchase common stock						211,112
Warrants exercise price						$ 0.001
Warrants term period						3 months
Mr. Duane C. Knight and Mr. Thomas B. Olson [Member]
Class of Stock [Line Items]
Proceeds from the exercise of warrants	$ 1,161
Private Placement [Member]
Class of Stock [Line Items]
Proceeds from issuance of stock through private placements			$ 100,000
Issuance of common stock			250,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	1 Months Ended						3 Months Ended
	Mar. 31, 2019shares	Sep. 30, 2018USD ($)$ / sharesshares	Jun. 30, 2018USD ($)	Mar. 31, 2017USD ($)	Aug. 31, 2016shares	Jan. 31, 2016USD ($)	Mar. 31, 2019USD ($)	Mar. 31, 2018USD ($)$ / sharesshares	Mar. 31, 2016shares	Jan. 31, 2016CAD ($)
Loss Contingencies [Line Items]
Research and development							$ 35,000	$ 10,000
Warrants Issued to Purchase Common Stock | shares								250,000
Warrants exercise price | $ / shares								$ 0.75
Research Institute of the McGill University Health Centre [Member] | April 2019 [Member]
Loss Contingencies [Line Items]
Research and development							$ 35,000
Four New Member Scientific Advisory Board [Member]
Loss Contingencies [Line Items]
Warrants Issued to Purchase Common Stock | shares		35,000
Warrants exercise price | $ / shares		$ 0.01
Paid annual fee		$ 25,000
Warrants exercised | shares	35,000
Research Agreement [Member]
Loss Contingencies [Line Items]
Research and development			$ 65,000	$ 130,000		$ 130,000
Agreement term				1 year		1 year
Agreement term, description				The Company paid these installment payments in July and October 2017 leaving no balance due
McGill [Member]
Loss Contingencies [Line Items]
Additional issuance of common stock | shares					300,000
Equity Method Investment, Ownership Percentage					5.00%
Series A financing [Member]
Loss Contingencies [Line Items]
Percentage of Issued and Outstanding Shares Issued As Milestone Payments									5.00%
Common Stock Shares Issued for Milestone Payment | shares									1,652,632
CAD Currency [Member]
Loss Contingencies [Line Items]
Annual royalty expense						$ 5,000
Royalty [Member]
Loss Contingencies [Line Items]
Annual revenue from royalty, percentage						3.00%
Androgen Replacement Treatment [Member] | First US Patent [Member]
Loss Contingencies [Line Items]
Accrued milestone payments						$ 3,750
Androgen Replacement Treatment [Member] | CAD Currency [Member] | First US Patent [Member]
Loss Contingencies [Line Items]
Milestone payments for treatment										$ 5,000
Androgen Replacement Treatment [Member] | CAD Currency [Member] | Investigational New Drug Application or Regulatory Filing [Member]
Loss Contingencies [Line Items]
Milestone payments for treatment										25,000
Androgen Replacement Treatment [Member] | CAD Currency [Member] | First Phase II Clinical Study [Member]
Loss Contingencies [Line Items]
Milestone payments for treatment										50,000
Androgen Replacement Treatment [Member] | CAD Currency [Member] | First Phase III Clinical Study [Member]
Loss Contingencies [Line Items]
Milestone payments for treatment										100,000
Androgen Replacement Treatment [Member] | CAD Currency [Member] | Receipt of Regulatory Approval [Member]
Loss Contingencies [Line Items]
Milestone payments for treatment										300,000
Alzheimer Disease [Member] | CAD Currency [Member] | First US Patent [Member]
Loss Contingencies [Line Items]
Milestone payments for treatment										5,000
Alzheimer Disease [Member] | CAD Currency [Member] | Receipt of Regulatory Approval [Member]
Loss Contingencies [Line Items]
Milestone payments for treatment										200,000
Alzheimer Disease [Member] | CAD Currency [Member] | Filing of a 510(K) or PMA Application [Member]
Loss Contingencies [Line Items]
Milestone payments for treatment										$ 50,000

Share-based Compensation (Detai

Share-based Compensation (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Feb. 28, 2018	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Issued to Purchase Common Stock		250,000
Warrants exercise price		$ 0.75
Share-based compensation		$ 336,926
December 2022 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Issued to Purchase Common Stock		400,000	400,000
Warrant expired date		Dec. 31, 2022	Dec. 31, 2022
February 2021 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Issued to Purchase Common Stock		460,000	460,000
Warrant expired date		Feb. 28, 2021	Feb. 28, 2021
Officers [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Issued to Purchase Common Stock				750,000
Warrants exercise price				$ 0.40
Share-based compensation		$ 20,502
Business, Legal and Scientific Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Issued to Purchase Common Stock		860,000	860,000
Warrants exercise price		$ 0.01	$ 0.01
Share-based compensation	$ 336,926

Share-based Compensation - Sche

Share-based Compensation - Schedule of Estimated Fair values of Warrants Granted Using the Black-Scholes Option Pricing Model (Details) - $ / shares	1 Months Ended	2 Months Ended
	Mar. 31, 2017	Feb. 28, 2018
Warrant One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.55%
Expected term	3 years
Volatility rate	154.00%
Dividend yield	0.00%
Fair value	$ 0.33
Warrant Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate, minimum		2.33%
Risk free interest rate, maximum		2.34%
Expected term		2 years 6 months
Volatility rate, minimum		182.00%
Volatility rate, maximum		217.00%
Dividend yield		0.00%
Fair value		$ 0.39